TIMI 14 evaluated the benefit of abciximab bolus plus 12 hour infusion alone or in conjunction with reduced dose thrombolytic therapy among patients presenting with ST elevation myocardial infarction. MAIN RESULTS:Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trialCirculation. 1999 Jun 1;99(21):2720-32. PRESENTATIONS TIMI 14 Slides … Continue reading TIMI 14